FRM
NKTR icon

Fox Run Management’s Nektar Therapeutics NKTR Stock Holding History

Fox Run Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,871
Closed -$448K – 1183
2026
Q1 		$448K Sell
6,871
-19,651
-74% -$1.12M 0.08% 488
2025
Q4 		$1.12M Buy
+26,522
New +$1.48M 0.17% 163
2022
Q1 		– Sell
-926
Closed -$188K – 635
2021
Q4 		$188K Buy
+926
New +$201K 0.11% 375
2020
Q1 		– Sell
-1,056
Closed -$342K – 286
2019
Q4 		$342K Buy
+1,056
New +$306K 0.28% 134
2019
Q1 		– Sell
-778
Closed -$384K – 622
2018
Q4 		$384K Buy
+778
New +$470K 0.2% 191
2018
Q3 		– Sell
-345
Closed -$253K – 741
2018
Q2 		$253K Buy
345
+214
+163% +$247K 0.08% 498
2018
Q1 		$209K Buy
+131
New +$169K 0.05% 618

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's NKTR Position: Q2 2026 in Review

Fox Run Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 6,871 shares — an estimated $448K sold.

Fox Run Management first reported a position in NKTR in Q1 2018 and held it in 7 quarters. The position peaked at $1.12M in Q4 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Fox Run Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 6,871 Nektar Therapeutics shares in Q2 2026, an estimated $448K.
  • Fox Run Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 7 quarters.
  • Fox Run Management's Nektar Therapeutics position peaked at $1.12M in Q4 2025.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.